MXJL05000010A - Compuestos de fenil-aza-benzimidazol para modular la ige e inhibir la proliferacion celular. - Google Patents

Compuestos de fenil-aza-benzimidazol para modular la ige e inhibir la proliferacion celular.

Info

Publication number
MXJL05000010A
MXJL05000010A MXJL05000010A MXJL05000010A MXJL05000010A MX JL05000010 A MXJL05000010 A MX JL05000010A MX JL05000010 A MXJL05000010 A MX JL05000010A MX JL05000010 A MXJL05000010 A MX JL05000010A MX JL05000010 A MXJL05000010 A MX JL05000010A
Authority
MX
Mexico
Prior art keywords
aza
phenyl
cellular proliferation
benzimidazole compounds
ige
Prior art date
Application number
MXJL05000010A
Other languages
English (en)
Spanish (es)
Inventor
C Sircar Jagadish
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of MXJL05000010A publication Critical patent/MXJL05000010A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXJL05000010A 2002-09-12 2003-09-12 Compuestos de fenil-aza-benzimidazol para modular la ige e inhibir la proliferacion celular. MXJL05000010A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41076102P 2002-09-12 2002-09-12
PCT/US2003/030962 WO2004024897A2 (en) 2002-09-12 2003-09-12 PHENYL-AZA-BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION

Publications (1)

Publication Number Publication Date
MXJL05000010A true MXJL05000010A (es) 2005-06-07

Family

ID=31994198

Family Applications (1)

Application Number Title Priority Date Filing Date
MXJL05000010A MXJL05000010A (es) 2002-09-12 2003-09-12 Compuestos de fenil-aza-benzimidazol para modular la ige e inhibir la proliferacion celular.

Country Status (17)

Country Link
US (1) US7256287B2 (cg-RX-API-DMAC10.html)
EP (1) EP1546157A4 (cg-RX-API-DMAC10.html)
JP (1) JP2006503048A (cg-RX-API-DMAC10.html)
KR (1) KR20050050102A (cg-RX-API-DMAC10.html)
CN (1) CN1694889A (cg-RX-API-DMAC10.html)
AR (1) AR041252A1 (cg-RX-API-DMAC10.html)
AU (1) AU2003279729A1 (cg-RX-API-DMAC10.html)
BR (1) BR0314235A (cg-RX-API-DMAC10.html)
CA (1) CA2498495A1 (cg-RX-API-DMAC10.html)
MX (1) MXJL05000010A (cg-RX-API-DMAC10.html)
NZ (1) NZ538547A (cg-RX-API-DMAC10.html)
PE (1) PE20050036A1 (cg-RX-API-DMAC10.html)
PL (1) PL375811A1 (cg-RX-API-DMAC10.html)
RU (1) RU2005109911A (cg-RX-API-DMAC10.html)
TW (1) TWI276631B (cg-RX-API-DMAC10.html)
WO (1) WO2004024897A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200502738B (cg-RX-API-DMAC10.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
BR0208010A (pt) * 2001-03-12 2004-12-21 Avanir Pharmaceuticals Composto de benzimidazol para modulação de ige e inibição de proliferação celular
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
CN1902193B (zh) 2003-12-04 2011-07-13 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的喹喔啉
JP5065034B2 (ja) * 2004-10-13 2012-10-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キナーゼ阻害剤として適しているｎ，ｎ’−ジフェニル尿素誘導体
CA2589877A1 (en) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
EP1833829A2 (en) * 2004-12-23 2007-09-19 F. Hoffmann-Roche AG Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
EP1912987A1 (en) 2005-08-01 2008-04-23 F. Hoffmann-Roche AG Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
BRPI0716477A2 (pt) 2006-09-06 2014-03-18 Hoffmann La Roche Derivados heteroarila como inibidores de quinase protéica
WO2009111278A2 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
CN105473581B (zh) 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
KR102307566B1 (ko) 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
CA2919948C (en) 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
JP6392352B2 (ja) 2013-12-19 2018-09-19 ノバルティス アーゲー リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体
CN103819398B (zh) * 2014-01-24 2016-05-04 河北科技大学 4-氨基-2-氯-3-硝基吡啶的合成方法
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
HK1245246A1 (zh) 2014-12-01 2018-08-24 恒翼生物医药科技(上海)有限公司 作为溴域抑制剂的取代吡啶酮
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
US20190263799A1 (en) * 2015-12-14 2019-08-29 Zenith Epigenetics Ltd. 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
CA3196620A1 (en) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
US20220127231A1 (en) * 2020-10-27 2022-04-28 Shilpa Medicare Ltd Process for the prepartion of amifampridine phosphate
KR102818206B1 (ko) * 2021-07-12 2025-06-11 한양대학교 에리카산학협력단 인다졸일 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도
CN117924278A (zh) * 2024-01-19 2024-04-26 四川大学 一种二胺单体、聚酰亚胺聚合物、芳香族聚酰胺聚合物及其制备方法和用途

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985891A (en) * 1973-02-03 1976-10-12 Boehringer Ingelheim Gmbh 2-Phenyl-imidazo (4,5-b)pyridines and salts thereof
DE3224512A1 (de) * 1982-07-01 1984-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4510158A (en) * 1984-03-05 1985-04-09 Sterling Drug Inc. 2-Phenylindole derivatives, their use as complement inhibitors
WO1986006739A1 (en) 1985-05-03 1986-11-20 The Foxboro Company Distillation cut point control
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US5206257A (en) * 1987-03-05 1993-04-27 May & Baker Limited Pesticidal method using 2-phenylimidazole derivatives
JP2630432B2 (ja) * 1987-08-24 1997-07-16 コニカ株式会社 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料
EP0327283B1 (en) 1988-02-02 1993-08-18 Schering Biotech Corporation Method of reducing immunoglobulin e responses
JP2700475B2 (ja) 1988-07-30 1998-01-21 コニカ株式会社 非線形光学材料および非線形光学素子
IT1232252B (it) 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
EP0415886A3 (en) 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
FR2658511B1 (fr) * 1990-02-16 1992-06-19 Union Pharma Scient Appl Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant.
WO1992002500A1 (fr) 1990-07-31 1992-02-20 Teikoku Hormone Mfg. Co., Ltd. Derive de 2-phenylindole
EP0469477B1 (en) 1990-08-02 1995-09-20 F. Hoffmann-La Roche Ag Antiallergic combination
US5633377A (en) * 1990-12-28 1997-05-27 Neurogen Corporation 4-piperidino- and piperazinomethyl-2-cyclohexyl imidazole derivatives; dopamine receptor subtype specific ligands
JPH06263993A (ja) 1991-01-21 1994-09-20 Konica Corp アゾメチン系染料、インドアニリン系染料及びインドフェノール系染料の製造法
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
CA2114114C (en) 1992-06-15 2005-05-03 Nigel Robert Arnold Beeley Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US5322847A (en) * 1992-11-05 1994-06-21 Pfizer Inc. Azabenzimidazoles in the treatment of asthma, arthritis and related diseases
PE27997A1 (es) 1994-04-29 1997-09-20 Lilly Co Eli Antagonistas de receptores de taquicininas
US5643893A (en) * 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5821258A (en) 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
DK0841924T3 (da) * 1995-08-02 2003-02-10 Univ Newcastle Ventures Ltd Benzimidazolforbindelser
US6387938B1 (en) * 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
US6153631A (en) 1996-10-23 2000-11-28 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
WO1998017267A1 (en) 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
CA2232467A1 (en) * 1997-03-20 1998-09-20 Richard A. Glennon Imidazoles with serotonin receptor binding activity
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
ID24054A (id) 1997-06-10 2000-07-06 Glaxo Group Ltd Glaxo Turunan turunan benzimidazol
GB9718833D0 (en) 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
RU2230553C2 (ru) * 1997-09-26 2004-06-20 Центарис АГ Способ модулирования функции серин/треонин протеинкиназы соединением на основе азабензимидазола, способ идентификации соединений, модулирующих функцию серин/треонин протеинкиназы, способ профилактики или лечения патологических состояний в организме, соединение на основе азабензимидазола, способ его синтеза и фармацевтическая композиция
US6100282A (en) * 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
US6369091B1 (en) * 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
MXPA00011470A (es) 1998-05-22 2002-10-17 Avanir Pharmaceuticals Analogos de bencimidazol como reguladores de la disminucion de ige.
US6303645B1 (en) * 1998-05-22 2001-10-16 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
TR200101239T2 (tr) 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
JP2002529537A (ja) * 1998-11-17 2002-09-10 ビーエーエスエフ アクチェンゲゼルシャフト ２−フェニルベンズイミダゾールおよび２−フェニルインドール、その製造方法ならびに使用
DK1133477T3 (da) 1998-11-27 2004-06-21 Abbott Gmbh & Co Kg Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
DE19939463A1 (de) 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6759425B2 (en) * 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
US6537994B2 (en) * 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
ES2236505T3 (es) 2001-03-12 2005-07-16 Janssen Pharmaceutica N.V. Procedimiento para la preparacin de compuestos de imidazol.
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
BR0208010A (pt) * 2001-03-12 2004-12-21 Avanir Pharmaceuticals Composto de benzimidazol para modulação de ige e inibição de proliferação celular
EA007339B1 (ru) * 2001-07-27 2006-08-25 Кьюэрис, Инк. Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2003270426A1 (en) * 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
PL378919A1 (pl) * 2003-04-10 2006-06-12 Avanir Pharmaceuticals Pochodne imidazolu do leczenia zaburzeń alergicznych i nadmiernego rozrostu
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases

Also Published As

Publication number Publication date
WO2004024897A2 (en) 2004-03-25
PE20050036A1 (es) 2005-01-24
NZ538547A (en) 2007-05-31
TW200404784A (en) 2004-04-01
EP1546157A4 (en) 2007-02-28
TWI276631B (en) 2007-03-21
KR20050050102A (ko) 2005-05-27
EP1546157A2 (en) 2005-06-29
WO2004024897A3 (en) 2004-08-26
ZA200502738B (en) 2007-04-25
BR0314235A (pt) 2005-08-09
US7256287B2 (en) 2007-08-14
JP2006503048A (ja) 2006-01-26
AR041252A1 (es) 2005-05-11
PL375811A1 (en) 2005-12-12
AU2003279729A1 (en) 2004-04-30
CA2498495A1 (en) 2004-03-25
RU2005109911A (ru) 2006-04-27
US20040116466A1 (en) 2004-06-17
CN1694889A (zh) 2005-11-09

Similar Documents

Publication Publication Date Title
WO2004024897A3 (en) PHENYL-AZA-BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
MXJL05000009A (es) Compuestos de fenilindon para modular la ige e inhibir la proliferacion celular.
MXJL03000027A (es) Compuestos de benzimidazol para modular la ige e inhibir la proliferacion celular.
TW200503695A (en) Imidazole derivatives for treatment of allergic and hyperproliferative disorders
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
IL139828A0 (en) COMPOUNDS HAVING IgE AFFECTING PROPERTIES
TW200510416A (en) P38 inhibitors and methods of use thereof
ATE494280T1 (de) Stereoisomerisch angereicherte 3-aminocarbonyl- bicyclohepten-pyrimidindiamin-verbindungen und ihre verwendungen
MXPA04004064A (es) Derivados heteroaromaticos de carboxamida para el tratramiento de la inflamacion.
EP1608627A4 (en) BICYCLIC ANILID SPIROHYDANTOINS AS CGRP RECEPTOR ANTAGONISTS
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
EP1613368A4 (en) Carboxamide-spiro hydantoin-CGRP Receptor Antagonists
CY1112253T1 (el) Ενωσεις διαμινοτριαζολιου χρησιμες ως αναστολεις κινασης πρωτεϊνης
TW200509892A (en) Novel aminobenzophenone compounds
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
DE602004017332D1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
SE0102716D0 (sv) Novel compounds
GEP20053590B (en) Phenyl Heterocyclyl Ether Derivatives as Serotonin Re-Uptake Inhibitors
TW200740808A (en) Inhibiteurs de proteines kinases
EA200600777A1 (ru) N-замещённые пиразолилкарбоксанилиды
WO2005011611A3 (en) Bicyclic compounds and compositions as pdf inhibitors
UA94054C2 (en) Nitrocatechol derivatives as comt inhibitors
TW200716561A (en) P38 inhibitors and methods of use thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal